Lilly’s Zepbound plus Taltz boosts arthritis relief, weight loss in late-stage trial

Jan 8 () - Eli Lilly said on Thursday a late-stage trial showed its weight-loss drug Zepbound, used with ​its psoriatic ...
Healio

Lilly: Taltz plus Zepbound superior to monotherapy for psoriatic arthritis, weight loss

Combination therapy with ixekizumab and tirzepatide bested monotherapy with ixekizumab alone in both psoriatic arthritis and ...

Nvidia, Eli Lilly to spend $1 billion over five years on joint research lab

Nvidia and U.S. pharma giant Eli Lilly will spend $1 billion building a new joint research lab in the San Francisco Bay area ...

Lilly’s Zepbound Plus Arthritis Drug Taltz Eases Joint Pain

Patients given a combination of Eli Lilly & Co.’s weight-loss shot Zepbound and arthritis drug Taltz saw a greater ...
Fierce Pharma

Lilly touts promise of Zepbound-Taltz combo in patients with obesity and psoriatic arthritis

In an open-label phase 3b trial, the co-administration of Lilly’s IL-17A antagonist Taltz (ixekizumab) and dual GIP/GLP-1 ...

Eli Lilly Study Finds Zepbound Dual Treatment Improves Arthritis, Helps Patients Lose Weight

Eli Lilly said combining Taltz and Zepbound improved arthritis symptoms and drove meaningful weight loss, outperforming Taltz ...
STAT

Eli Lilly’s Zepbound, on top of immunology drug, helped reduce psoriatic arthritis symptoms

Eli Lilly said Thursday that adding its weight loss drug Zepbound on top of its immunology therapy Taltz helped obese ...

FDA asks Lilly, Novo to remove suicide warning related to GLP-1 obesity drugs

Novo Nordisk (NVO) stock and Eli Lilly (LLY) stock are in focus as the FDA seeks to remove suicide-risk warnings related to their GLP-1 weight-loss drugs. Read more here.

Bull of the Day: Eli Lilly (LLY)

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.